PRECIGEN, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
PRECIGEN, INC. (PGEN) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $41.58 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2018-03-01
- PRECIGEN, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2017-12-31 was $9.63M, a 16.80% decline year-over-year.
- PRECIGEN, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2017-09-30 was $12.06M, a 11.72% increase year-over-year.
- PRECIGEN, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2017-06-30 was $12.00M, a 80.39% increase year-over-year.
- PRECIGEN, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2017-03-31 was $7.89M, a 40.05% decline year-over-year.
- PRECIGEN, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2017 was $41.58M, a 1.43% decline from fiscal 2016.
- PRECIGEN, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2016 was $42.18M, a 9.03% increase from fiscal 2015.
- PRECIGEN, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2015 was $38.69M, a 77.07% increase from fiscal 2014.
- PRECIGEN, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2014 was $21.85M, a 648.00% increase from fiscal 2013.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2017-12-31 | $9.63M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $21.68M derived: sum of 2 quarters · filed 2018-03-01 | $33.68M derived: sum of 3 quarters · filed 2018-03-01 | $41.58M 10-K · filed 2018-03-01 |
| 2017-09-30 | $12.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $24.05M derived: sum of 2 quarters · filed 2017-11-09 | $31.95M 10-Q · filed 2017-11-09 | $43.52M derived: sum of 4 quarters · filed 2018-03-01 |
| 2017-06-30 | $12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $19.89M 10-Q · filed 2017-08-09 | $31.46M derived: sum of 3 quarters · filed 2018-03-01 | $42.26M derived: sum of 4 quarters · filed 2018-03-01 |
| 2017-03-31 | $7.89M 10-Q · filed 2017-05-10 | $19.46M derived: sum of 2 quarters · filed 2018-03-01 | $30.26M derived: sum of 3 quarters · filed 2018-03-01 | $36.91M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-12-31 | $11.57M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $22.36M derived: sum of 2 quarters · filed 2018-03-01 | $29.01M derived: sum of 3 quarters · filed 2018-03-01 | $42.18M 10-K · filed 2018-03-01 |
| 2016-09-30 | $10.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $17.44M derived: sum of 2 quarters · filed 2016-11-09 | $30.61M 10-Q · filed 2016-11-09 | $42.75M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $6.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $19.82M 10-Q · filed 2016-08-09 | $31.96M derived: sum of 3 quarters · filed 2018-03-01 | $40.34M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $13.17M 10-Q · filed 2016-05-10 | $25.31M derived: sum of 2 quarters · filed 2018-03-01 | $33.69M derived: sum of 3 quarters · filed 2018-03-01 | $41.60M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $12.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $20.52M derived: sum of 2 quarters · filed 2018-03-01 | $28.43M derived: sum of 3 quarters · filed 2018-03-01 | $38.69M 10-K · filed 2018-03-01 |
| 2015-09-30 | $8.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $16.29M derived: sum of 2 quarters · filed 2015-11-09 | $26.55M 10-Q · filed 2015-11-09 | $33.53M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $7.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $18.17M 10-Q · filed 2015-08-10 | $25.14M derived: sum of 3 quarters · filed 2017-03-01 | $29.39M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $10.26M 10-Q · filed 2015-05-11 | $17.24M derived: sum of 2 quarters · filed 2017-03-01 | $21.49M derived: sum of 3 quarters · filed 2017-03-01 | $28.33M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $6.98M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $11.23M derived: sum of 2 quarters · filed 2017-03-01 | $18.07M derived: sum of 3 quarters · filed 2017-03-01 | $21.85M 10-K · filed 2017-03-01 |
| 2014-09-30 | $4.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $11.10M derived: sum of 2 quarters · filed 2014-11-13 | $14.87M 10-Q · filed 2014-11-13 | $15.95M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $6.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $10.62M 10-Q · filed 2014-08-14 | $11.70M derived: sum of 3 quarters · filed 2016-02-29 | $12.35M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $3.77M 10-Q · filed 2014-05-09 | $4.85M derived: sum of 2 quarters · filed 2016-02-29 | $5.50M derived: sum of 3 quarters · filed 2016-02-29 | |
| 2013-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $1.73M derived: sum of 2 quarters · filed 2016-02-29 | $2.92M 10-K · filed 2016-02-29 | |
| 2013-09-30 | $645.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-07 | $1.84M 10-Q · filed 2013-11-07 | ||
| 2013-06-30 | $1.20M 10-Q/A · filed 2013-10-21 | |||
| 2012-12-31 | $1.46M 10-K · filed 2015-03-02 | |||
| 2011-12-31 | $983.00K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |